NeuroOne Medical Technologies
NMTC
18 hedge funds and large institutions have $1.64M invested in NeuroOne Medical Technologies in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 6 closing their positions.
3,050% more call options, than puts
Call options by funds: $63K | Put options by funds: $2K
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
23% more capital invested
Capital invested by funds: $1.34M → $1.64M (+$304K)
0.17% more ownership
Funds ownership: 0.87% → 1.04% (+0.17%)
10% less funds holding
Funds holding: 20 → 18 (-2)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$202K |
| 2 |
Goldman Sachs
New York
|
+$104K |
| 3 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$85.7K |
| 4 |
JWCA
J.W. Cole Advisors
Tampa,
Florida
|
+$39.3K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$36.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$75.8K |
| 2 |
Jane Street
New York
|
-$33K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$15.3K |
| 4 |
HF
HRT Financial
New York
|
-$10K |
| 5 |
MW
Marcum Wealth
Cleveland,
Ohio
|
-$9.91K |
NMTC Hedge Fund Activity: Q1 2025 in Review
18 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in NeuroOne Medical Technologies (NMTC) for Q1 2025, worth a combined $1.64M — up 23% from $1.34M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of NMTC and 4 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 5 added.
The largest buyer was Vanguard Group, adding an estimated $202K. The largest seller was Citadel Advisors, cutting an estimated $75.8K.
- 18 institutional investors held NeuroOne Medical Technologies (NMTC) as of Q1 2025, down from 20 in Q4 2024.
- Funds reported $1.64M of NeuroOne Medical Technologies stock for Q1 2025, up 23% quarter-over-quarter.
- 4 funds opened new NeuroOne Medical Technologies positions in Q1 2025 and 6 closed out, a net change of -2 holders.
- The largest NeuroOne Medical Technologies buyer in Q1 2025 was Vanguard Group, an estimated $202K added.
- The largest NeuroOne Medical Technologies seller in Q1 2025 was Citadel Advisors, an estimated $75.8K sold.
Based on aggregated 13F filings for Q1 2025.